CSIMarket
 


Kalvista Pharmaceuticals Inc   (KALV)
Other Ticker:  
 

Cumulative Kalvista Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

KALV's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

KALV Working Capital Ratio for Trailing Twelve Months Period

(Oct 31 2022)
II. Quarter
(Jul 31 2022)
I. Quarter
(Apr 30 2022)
IV. Quarter
(Jan 31 2022)
III. Quarter
(Oct 31 2021)
II. Quarter
Y / Y Current Liabilities Growth 12.09 % 19.28 % 18.94 % 45.71 % 0.77 %
Y / Y Current Assets Growth -35.51 % -31.78 % -26.72 % 243.12 % 225.32 %
Working Capital Ratio for Trailing Twelve Months Period 19.07 21.88 24.97 28.28 25.87
Total Ranking # 185 # 239 # 199 # 165 # 147
Seq. Current Liabilities Growth 17.83 % -17.58 % 22.74 % -5.98 % 25.4 %
Seq. Current Assets Growth -11.26 % -12 % -9.71 % -8.54 % -6.13 %


Working Capital Ratio for Trailing Twelve Months Period Comment
On the trailing twelve months basis Due to increase in Current Liabilities in the II. Quarter to $10 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 19.07 below Kalvista Pharmaceuticals Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Kalvista Pharmaceuticals Inc . While Working Capital Ratio for Trailing Twelve Months Period overall ranking has improved so far to 185, from total ranking in previous quarter at 239.

What is Working Capital Ratio?
More about KALV
Working Capital Ratio KALV in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 70
Sector # 109
S&P 500 # 185


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
25.5 12.73 3.41
(Jan 31 2022)   (Oct 31 2018)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Oct 31 2022, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Design Therapeutics Inc   52.15 
Aerovate Therapeutics Inc.  50.43 
Xbiotech Inc   50.15 
Atossa Therapeutics Inc   47.21 
Nuvation Bio Inc   45.24 
Annovis Bio inc   43.66 
Anebulo Pharmaceuticals Inc  40.07 
Xenon Pharmaceuticals Inc   40.02 
Terns Pharmaceuticals Inc   39.39 
Zomedica Corp   38.29 
Infinity Pharmaceuticals Inc   35.89 
Artelo Biosciences Inc   35.70 
Theseus Pharmaceuticals inc   34.95 
Cocrystal Pharma Inc.  33.88 
Nextcure Inc   32.81 
Stoke Therapeutics Inc   32.10 
Eqrx Inc   31.83 
Rezolute Inc   30.44 
Nanoviricides inc   30.30 
Day One Biopharmaceuticals Inc   30.05 
Immix Biopharma Inc   29.94 
Synaptogenix Inc   28.93 
Xortx Therapeutics Inc   28.78 
Nuvalent Inc   28.46 
Kezar Life Sciences Inc   28.23 
Diamedica Therapeutics Inc   28.02 
Edgewise Therapeutics inc.  26.97 
Merrimack Pharmaceuticals Inc  26.97 
Spruce Biosciences Inc   26.94 
Janux Therapeutics Inc   26.91 


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

STEK's Profile

Stock Price

STEK's Financials

Business Description

Fundamentals

Charts & Quotes

STEK's News

Suppliers

STEK's Competitors

Customers & Markets

Economic Indicators

STEK's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071